comparemela.com

Latest Breaking News On - Domain antibodies - Page 1 : comparemela.com

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer | Antibodies

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

New jerseyUnited statesRoger danseyTisotumab vedotinPfizer incDrug administrationEuropean network of gynaecological oncological trial groupsGynecologic oncology groupLancet glob healthEuropean medicines agencyEuropean unionMetastatic cervical cancerDenmarki februaryLooking informationFactors that may affect futureChief executive officer

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market | Antibodies

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

United statesCoherus biosciencesChoroidal neovascularizationKeren haruviCoherus biosciences incGenentech united states incAmerican academy of ophthalmologySwitzerlandi januaryPresident sandoz north americaAge related macular degenerationEdema following retinal vein occlusionMacular edemaSafety informationFull prescribing informationGenentech united statesFull prescribing

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial | Antibodies

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial

City ofUnited kingdomSouth koreaUnited statesSusan galbraithAstrazeneca imfinziTransarterial chemoembolizationRiccardo lencioniDaiichi sankyoWorld health organisationCancer imaging programBiosciences incMerck co incUnited kingdomi novemberInterventional radiologyPisa university hospital

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023 | Antibodies

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023

European society for medical oncologyQilu pharmaceuticalShowcase novel anti cancer drugChinai octoberEuropean societyMedical oncologyAnnual congressResponse evaluation criteriaSolid tumorsTherapeutic antibodiesAntibody drug conjugatesBiosimilar antibodiesBiosuperior antibodiesAntibody fragmentsDomain antibodies

LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform

Today, LabGenius, a pioneer in the use of AI and machine learning for antibody discovery, releases new data from its antibody discovery platform following a multi-year collaboration with Sanofi.

France generalFrom labgeniussepBig pharmaDomain antibodiesAntibody discoveryMachine learning

vimarsana © 2020. All Rights Reserved.